These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34934078)

  • 21. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative estimation of regional brain iron with magnetic resonance imaging.
    Martin WR
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S215-8. PubMed ID: 20082994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
    Safai A; Prasad S; Chougule T; Saini J; Pal PK; Ingalhalikar M
    Hum Brain Mapp; 2020 Apr; 41(5):1323-1333. PubMed ID: 31778276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.
    Kim TH; Lee JH
    PLoS One; 2014; 9(11):e112512. PubMed ID: 25386854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
    Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
    Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.
    Guan X; Xuan M; Gu Q; Huang P; Liu C; Wang N; Xu X; Luo W; Zhang M
    NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 26853890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
    Kashihara K; Shinya T; Higaki F
    J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
    Martin WR; Wieler M; Gee M
    Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nigral iron deposition in common tremor disorders.
    Homayoon N; Pirpamer L; Franthal S; Katschnig-Winter P; Kögl M; Seiler S; Wenzel K; Hofer E; Deutschmann H; Fazekas F; Langkammer C; Ropele S; Schmidt R; Schwingenschuh P
    Mov Disord; 2019 Jan; 34(1):129-132. PubMed ID: 30536988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance imaging assessment of substantia nigral iron deposition in Parkinson's disease: a meta-analysis.
    Liu GL; Zhang HW; Zha CB; Fan TW; Chen ST; Shen TT; He K
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):899-906. PubMed ID: 38375696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI.
    Ahmadi SA; Bötzel K; Levin J; Maiostre J; Klein T; Wein W; Rozanski V; Dietrich O; Ertl-Wagner B; Navab N; Plate A
    Neuroimage Clin; 2020; 26():102185. PubMed ID: 32050136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
    Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
    Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic impacts on nigral iron deposition in Parkinson's disease: A preliminary quantitative susceptibility mapping study.
    Wu J; Guo T; Zhou C; Bai X; Liu X; Gu L; Xuan M; Gu Q; Huang P; Song Z; Zhang B; Xu X; Zhang M; Guan X
    CNS Neurosci Ther; 2023 Jul; 29(7):1776-1784. PubMed ID: 36852447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study.
    Martínez-Hernández R; Montes S; Higuera-Calleja J; Yescas P; Boll MC; Diaz-Ruiz A; Rios C
    Neurochem Res; 2011 Nov; 36(11):2111-5. PubMed ID: 21706376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.
    Ayton S; Lei P
    Biomed Res Int; 2014; 2014():581256. PubMed ID: 24527451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.